Mechanisms of SSRI Therapy and Discontinuation
The DOI matches its Crossref record; 138 of the 138 references it cites were found in a registry or an index.
Abstract
SSRIs are one of the most widely used drug therapies in primary care and psychiatry, and central to the management of the most common mental health problems in today's society. Despite this, SSRIs suffer from a slow onset of therapeutic effect and relatively poor efficacy as well as adverse effects, with recent concerns being focused on a disabling SSRI discontinuation syndrome. The mechanism underpinning their therapeutic effect has long shifted away from thinking that SSRIs act simply by increasing 5-HT in the synapse. Rather, a current popular view is that increased 5-HT is just the beginning of a series of complex downstream signalling events, which trigger changes in neural plasticity at the functional and structural level. These changes in plasticity are then thought to interact with neuropsychological processes to enhance re-learning of emotional experiences that ultimately brings about changes in mood. This compelling view of SSRI action is underpinning attempts to understand fast-acting antidepressants, such as ketamine and psychedelic drugs, and aid the development of future therapies. An important gap in the theory is evidence that changes in plasticity are causally linked to relevant behavioural effects. Also, predictions that the SSRI-induced neural plasticity might have applicability in other areas of medicine have not yet been borne out. In contrast to the sophisticated view of the antidepressant action of SSRIs, the mechanism underpinning SSRI discontinuation…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321
Cipriani, A., Furukawa, T. A., Salanti, G., Chaimani, A., Atkinson, L. Z., Ogawa, Y., Leucht, S., Ruhe, H. G., Turner, E. H., Higgins, J. P. T., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32802-7 · Cited by 3,541
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
for the ENIGMA-Major Depressive Disorder Working Group, Schmaal, L., Veltman, D. J., van Erp, T. G. M., Sämann, P. G., Frodl, T., Jahanshad, N., Loehrer, E., Tiemeier, H., Hofman, A., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.69 · Cited by 1,172
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
The serotonin theory of depression: a systematic umbrella review of the evidence
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01661-0 · Cited by 960
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925
Cited by
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“Additionally, SSRIs are notorious for their required lengthy trial period before seeing therapeutic effects, as well as the litany of side effects associated with medication use, discontinuation, and abrupt cessation [256].”
Zhang, Y., Wang, N., Zhang, L., Zhuang, Y., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2025) · MedComm · doi:10.1002/mco2.70383 · Cited by 59
Trends in research on novel antidepressant treatments
Zelek-Molik, A., & Litwa, E. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1544795 · Cited by 35
“Among these, SSRIs are the most commonly used today, as they primarily address the hypoactivity of monoamine neurotransmitter systems (Sharp and Collins, 2023).”
Цейликман, В. Э., Tseilikman, O. B., Karpenko, M. N., Traktirov, D. S., Obukhova, D. A., Shatilov, V. A., Zhukov, M. S., Валерьевич, М. Г., Yegorov, O. N., Aristov, M. R., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12112455 · Cited by 24
“Moreover, the long-term use of SSRIs is associated with several adverse effects, such as impaired spermatogenesis, liver damage, and others [32,33].”
Lewis, C. P., Klimes‐Dougan, B., Croarkin, P. E., & Cullen, K. R. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02168-2 · Cited by 34
Neuropsychopharmacology of hallucinogenic and non‐hallucinogenic 5‐HT 2A receptor agonists
Sharp, T., & Ippolito, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70050 · Cited by 17
“…drugs such as selective serotonin reuptake inhibitors (SSRIs) is that, over a course of treatment of several weeks, they activate a programme of gene expression that generates neuroplastic changes to facilitate emotional relearning (as reviewed in Sharp & Collins, 2024; Sharp & Cowen, 2011).”
Self-citationWu, P., Hurst, J. H., French, A., Chrestensen, M., & Goldstein, B. A. (2025) · JMIR Medical Informatics · doi:10.2196/63740 · Cited by 8
“…reuptake inhibitor (the predominant medication class for depression and certain anxiety disorders) versus other type of psycho-tropic medication [35], the presence or absence of a completed Patient Health Questionnaire-9 (PHQ-9), the PHQ-9 score (categorized as 0 ‐ 4=nonminimal, 5-9=mild,…”
Current Trends in Clinical Trials of Prodrugs
Boreski, D., Schmid, V. F., Bosquesi, P. L., dos Santos, J. L., Scarim, C. B., Reshetnikov, V., & Chin, C. M. (2025) · Pharmaceuticals · doi:10.3390/ph18020210 · Cited by 19
“SSRIs are the most prescribed due to their efficacy and fewer side effects compared to older classes [72].”
Bravi, B., Paolini, M., Maccario, M., Milano, C., Raffaelli, L., Melloni, E. M. T., Zanardi, R., Colombo, C., & Benedetti, F. (2024) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13764 · Cited by 10
Zwolińska, W., Bilska, K., Skibińska, M., Pytlińska, N., Słopień, A., & Dmitrzak‐Węglarz, M. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.02.038 · Cited by 6
Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model
Kandilakis, C. L., & Papatheodoropoulos, C. (2026) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00892 · Cited by 5
The psychedelic-peptide paradox: a hormetic hypothesis
Carter, C. S. (2025) · Comprehensive Psychoneuroendocrinology · doi:10.1016/j.cpnec.2025.100303 · Cited by 4
Fortier, L. M., Moyal, A. J., Dave, U., Burkhart, R. J., Adelstein, J. M., Strony, J. T., Sinkler, M. A., & Napora, J. K. (2025) · Injury · doi:10.1016/j.injury.2025.112236 · Cited by 5
Collins, H. M., Gullino, L. S., Fuller, C., Pinacho, R., Bannerman, D. M., & Sharp, T. (2025) · Neuropharmacology · doi:10.1016/j.neuropharm.2025.110541 · Cited by 3
Self-citationDobrea, C. M., Morgovan, C., Frum, A., Butucă, A., Chiş, A. A., Arseniu, A. M., Ghibu, S., Vonica, R. C., Gligor, F. G., Ilie, I. R. P., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041208 · Cited by 5
“…showing various DDIs being triggered due to SSRIs influencing the activity of several cytochrome P450 isoenzymes and by pharmacodynamic mechanisms [48], while for duloxetine, fewer interactions were described [49], and the same was true for venlafaxine, a molecule considered safer than other…”
Greydanus, D. E., Nazeer, A., & Patel, D. R. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.101853 · Cited by 4
Pharmacological treatment of major depression
Vázquez, G. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33580-8.00018-0 · Cited by 3
Kaschula, C. H., Engelbrecht, A., Makunga, N. P., Muller, M., de Villiers, A. J., Dube, K. M., Brand, S. J., Stroebel, J.-A., van Otterlo, W. A. L., & Wolmarans, D. W. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119974 · Cited by 3
Disruptions in serotonin- and kynurenine pathway metabolism in post-COVID: biomarkers and treatment
Rus, C. P. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1532383 · Cited by 5
Monoaminylation in Human Health and Disease: State of the Field, Challenges, and Emerging Directions
Zhao, Y., Zhang, H., Yang, Y., Chen, W., & Wang, Y. (2026) · Advanced Science · doi:10.1002/advs.202520653 · Cited by 3
Transforming Amino Acids into Serotonin 5-HT 2A Receptor Ligands Using Photochemistry
Beckett, J. O. S., Buzdygon, R., Nguyen, S. M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19817 · Cited by 1
Tolle, H. M., Luppi, A. I., Lawn, T., Roseman, L., Nutt, D. J., Carhart-Harris, R. L., & Mediano, P. A. M. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.02.662710 · Cited by 1
“These compounds act by inhibiting the reuptake of serotonin (5-HT) from the synaptic cleft through blockade of the serotonin transporter (5-HTT, a.k.a. SERT) [4].”
InfluentialZhang, W., Jin, Y., & Zhou, F. (2025) · Brain Sciences · doi:10.3390/brainsci15040384 · Cited by 2
“This 5-HT1A receptor neuroadaptive downregulation has been suggested to be critical to fluoxetine’s antidepressant effect [16,17,63].”
Tian, M., Yi, S., Zhao, L., Li, L., Fang, L., & Ru, Q. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100035 · Cited by 1
Relevant Pharmacology and Interventions
Watson, A., & Hand, S. (2024) · Springer eBooks · doi:10.1007/978-3-031-72862-4_3 · Cited by 1
Wu, D., Chen, Y., Izumoji, G., Qu, S., Wang, Y., He, X., Zhou, S., Jiang, Y., Sun, H., & Li, X. J. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1785271 · Cited by 1
“Selective Serotonin Reuptake Inhibitors (SSRIs) is the first artificially designed psychiatric drug commonly used to treat depression or other mental illnesses (75).”
Zhong, W., Rao, M., Zhou, Q., Leng, Z., Zhang, B., & Lin, Z. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1904032
Psychopharmacological Mechanisms of Antidepressant Withdrawal: Insights From Venlafaxine
McClure, E. W. (2026) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70061
Zhuang, J., Zhou, Y. K., Yu, G., Cheng, H., Chen, X., & Qian, R. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1845876
“Antidepressants enhance serotonergic transmission and promote neuroplastic changes that facilitate emotional relearning (159), while CBT addresses maladaptive cognitive patterns to reduce emotional distress (15).”
U.S. student pharmacists perspectives on the pharmacogenomics of escitalopram and aripiprazole
Beins, B., Salcedo, H., Grice, G. R., & Billon, C. (2026) · Pharmacogenomics · doi:10.1080/14622416.2026.2710850
Ameliorated potential and possible mechanisms of medicine food homology for depression
Huo, C., Li, Q., Cai, N., Teng, C., & Kou, J. (2026) · 3 Biotech · doi:10.1007/s13205-026-04912-x
Чорномидз, А. В., Vynychenko, A., & Lukanyuk, M. I. (2026) · Psychiatry Neurology and Medical Psychology · doi:10.26565/2312-5675-2026-35-11
Zaniewska, M. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00860-8
“Depending on the compound and stereoiso-mer, SSRIs may also interact with other targets, however, the affinity for these targets is much lower than to SERT [ 250].”
Pietruczuk, K., Rückemann-Dziurdzińska, K., Bierzanowski, S., Grabowski, K., Bryl, E., & Witkowski, J. M. (2026) · Research Square · doi:10.21203/rs.3.rs-9336198/v1
Beyond neurotransmission: the roles of serotonylation in physiological and pathological processes
Wang, J.-M., Zhang, F.-H., Chen, Y.-R., Chen, D.-N., Wang, X. L., Xie, H., Jiang-Feng, L. I., Luo, J.-D., & Xie, L.-P. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-026-00909-9 · Cited by 1
“The affinity between SSRIs and SERT was approximately 10–100 times greater than that between SSRIs and other neurotransmitter transporters or receptors [300].”
Niu, Y., Li, K., Zhan, K., Pi, M., Xiong, Q., Wang, J., Wang, X. J., Shu, X., Xia, Y., & Huang, M. (2026) · Biomolecules · doi:10.3390/biom16050639
“Current standard treatments, including selective serotonin reuptake inhibitors and cognitive behavioral therapy, are limited by suboptimal response rates, delayed therapeutic onset, and significant side effects [6].”
Campuzano-Bublitz, M. Á., Burgos-Edwards, A., Gayozo, E., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19020329
“Most antidepressant drugs in clinical use promote an increase in 5-HT availability, directly affecting serotonin turnover and reuptake and interacting with the 5-HT 1A and 5-HT 2 receptors [25].”
The evolution of SSRI research: trajectories of knowledge domains across four decades
Westphal, L., Gräf, D. D., & Hallgreen, C. E. (2026) · BMC Psychiatry · doi:10.1186/s12888-026-07867-8
“Collectively, these clusters illustrate how the original hypothesis of depression as a serotonin deficiency has shifted to increasingly complex and diverse theories involving neuroplasticity, the BDNF, and inflammatory processes [48–52].”
Xie, J.-X., & Zhou, L.-W. (2025) · Molecular Biology Reports · doi:10.1007/s11033-025-11357-7 · Cited by 1
Ramalho, C. V. R., Galvão, J. G. F. M., Coelho, C. I. H. M., et al. (2025) · Revista Multidisciplinar do Nordeste Mineiro · doi:10.61164/eepm2q42
Serotonin und psychiatrische Störungen
Erfurth, A. (2025) · psychopraxis neuropraxis · doi:10.1007/s00739-025-01114-7
“Bestimmte unerwünschte Arzneimittelwirkungen sind typisch für die Beeinflussung der serotoninergen Transmission, und zwar sowohl beim An-setzen als auch beim Absetzen [23].”
Juárez, J., la Torre, A. C. H. D., & Yepez, J. E. (2025) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2025.100060
Zhang, Y., Zhang, W., Yu, L., Shi, Y., Xu, M., Wang, H., Li, C., & Tian, J. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70068
Effects of Reducing Synaptic Plasticity on Resilience to Depression and Anxiety in ASCL1 Mouse Model
Gao, X. (2025) · Theoretical and Natural Science · doi:10.54254/2753-8818/2024.19967
Kaschula, C. H., Engelbrecht, A., Makunga, N. P., Muller, M., de Villiers, A. J., Mochoele, K. A., Brand, S. J., Stroebel, J.-A., van Otterlo, W. A. L., & Wolmarans, D. W. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5205877
Metadata
- Authors
- Sharp, T., & Collins, H.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Sharp, Trevor
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer International Publishing
- Published
- 2023
- Volume
- 66
- Pages
- 21-47
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W4388641323
- Semantic Scholar
- 552e950a7b67d0c9226bf70575d04b14cc9a3a47
- Cited by
- 55
- References
- 138
- Citations by year
- 2026: 24 · 2025: 28 · 2024: 3
- FWCI
- 51.18
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- selective serotonin reuptake inhibitors, antidepressant mechanism, serotonin, neuroplasticity, rapid-acting antidepressants, ketamine, psychedelics, mood regulation
- MeSH terms
- Animals, Antidepressive Agents, Humans, Neuronal Plasticity, Serotonin, Substance Withdrawal Syndrome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.